These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 24763037)

  • 21. PI3Kδ inhibition hits a sensitive spot in B cell malignancies.
    Vanhaesebroeck B; Khwaja A
    Cancer Cell; 2014 Mar; 25(3):269-71. PubMed ID: 24651009
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Idelalisib has activity in mantle cell lymphoma.
    Cancer Discov; 2014 May; 4(5):OF8. PubMed ID: 24795031
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells.
    Göckeritz E; Kerwien S; Baumann M; Wigger M; Vondey V; Neumann L; Landwehr T; Wendtner CM; Klein C; Liu N; Hallek M; Frenzel LP; Krause G
    Int J Cancer; 2015 Nov; 137(9):2234-42. PubMed ID: 25912635
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PI3K/p110{delta} is a novel therapeutic target in multiple myeloma.
    Ikeda H; Hideshima T; Fulciniti M; Perrone G; Miura N; Yasui H; Okawa Y; Kiziltepe T; Santo L; Vallet S; Cristea D; Calabrese E; Gorgun G; Raje NS; Richardson P; Munshi NC; Lannutti BJ; Puri KD; Giese NA; Anderson KC
    Blood; 2010 Sep; 116(9):1460-8. PubMed ID: 20505158
    [TBL] [Abstract][Full Text] [Related]  

  • 25. First PI3k inhibitor launches into crowded hematology markets.
    Morrison C
    Nat Biotechnol; 2014 Oct; 32(10):963-4. PubMed ID: 25299893
    [No Abstract]   [Full Text] [Related]  

  • 26. Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy.
    Okkenhaug K; Graupera M; Vanhaesebroeck B
    Cancer Discov; 2016 Oct; 6(10):1090-1105. PubMed ID: 27655435
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PI3Kδ inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma.
    Meadows SA; Vega F; Kashishian A; Johnson D; Diehl V; Miller LL; Younes A; Lannutti BJ
    Blood; 2012 Feb; 119(8):1897-900. PubMed ID: 22210877
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The PI3K pathway: clinical inhibition in chronic lymphocytic leukemia.
    Brown JR
    Semin Oncol; 2016 Apr; 43(2):260-4. PubMed ID: 27040704
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The catalytic phosphoinositol 3-kinase isoform p110δ is required for glioma cell migration and invasion.
    Luk SK; Piekorz RP; Nürnberg B; Tony To SS
    Eur J Cancer; 2012 Jan; 48(1):149-57. PubMed ID: 22079609
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structural, biochemical, and biophysical characterization of idelalisib binding to phosphoinositide 3-kinase δ.
    Somoza JR; Koditek D; Villaseñor AG; Novikov N; Wong MH; Liclican A; Xing W; Lagpacan L; Wang R; Schultz BE; Papalia GA; Samuel D; Lad L; McGrath ME
    J Biol Chem; 2015 Mar; 290(13):8439-46. PubMed ID: 25631052
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PI3Kδ inhibitors for the treatment of cancer: a patent review (2015-present).
    Feng Y; Cu X; Xin M
    Expert Opin Ther Pat; 2019 Dec; 29(12):925-941. PubMed ID: 31670985
    [No Abstract]   [Full Text] [Related]  

  • 32. Class IA Phosphatidylinositol 3-Kinase Isoform p110α Mediates Vascular Remodeling.
    Vantler M; Jesus J; Leppänen O; Scherner M; Berghausen EM; Mustafov L; Chen X; Kramer T; Zierden M; Gerhardt M; Ten Freyhaus H; Blaschke F; Sterner-Kock A; Baldus S; Zhao JJ; Rosenkranz S
    Arterioscler Thromb Vasc Biol; 2015 Jun; 35(6):1434-44. PubMed ID: 25908763
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PI3K-δ inhibition using CAL-101 exerts apoptotic effects and increases doxorubicin-induced cell death in pre-B-acute lymphoblastic leukemia cells.
    Safaroghli-Azar A; Bashash D; Sadreazami P; Momeny M; Ghaffari SH
    Anticancer Drugs; 2017 Apr; 28(4):436-445. PubMed ID: 28125433
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of WO2014075392 and WO2014075393, Merck's first PI3Kδ inhibitor filings.
    Norman P
    Expert Opin Ther Pat; 2014 Nov; 24(11):1277-82. PubMed ID: 25326077
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DW09849, a selective phosphatidylinositol 3-kinase (PI3K) inhibitor, prevents PI3K signaling and preferentially inhibits proliferation of cells containing the oncogenic mutation p110α (H1047R).
    Liu JL; Gao GR; Zhang X; Cao SF; Guo CL; Wang X; Tong LJ; Ding J; Duan WH; Meng LH
    J Pharmacol Exp Ther; 2014 Mar; 348(3):432-41. PubMed ID: 24361696
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ETP-46321, a dual p110α/δ class IA phosphoinositide 3-kinase inhibitor modulates T lymphocyte activation and collagen-induced arthritis.
    Aragoneses-Fenoll L; Montes-Casado M; Ojeda G; Acosta YY; Herranz J; Martínez S; Blanco-Aparicio C; Criado G; Pastor J; Dianzani U; Portolés P; Rojo JM
    Biochem Pharmacol; 2016 Apr; 106():56-69. PubMed ID: 26883061
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecules in medicine mini-review: isoforms of PI3K in biology and disease.
    Vanhaesebroeck B; Whitehead MA; Piñeiro R
    J Mol Med (Berl); 2016 Jan; 94(1):5-11. PubMed ID: 26658520
    [TBL] [Abstract][Full Text] [Related]  

  • 38. RP105 Engages Phosphatidylinositol 3-Kinase p110δ To Facilitate the Trafficking and Secretion of Cytokines in Macrophages during Mycobacterial Infection.
    Yu CH; Micaroni M; Puyskens A; Schultz TE; Yeo JC; Stanley AC; Lucas M; Kurihara J; Dobos KM; Stow JL; Blumenthal A
    J Immunol; 2015 Oct; 195(8):3890-900. PubMed ID: 26371254
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical drug interaction profile of idelalisib in healthy subjects.
    Jin F; Robeson M; Zhou H; Moyer C; Wilbert S; Murray B; Ramanathan S
    J Clin Pharmacol; 2015 Aug; 55(8):909-19. PubMed ID: 25760671
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Duvelisib, a new PI3K inhibitor for lymphoid malignancies.
    Lamanna N
    Clin Adv Hematol Oncol; 2020 Oct; 18(10):606-608. PubMed ID: 33201865
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.